DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20150363

Pathophysiological and pharmacological modulation of melatonergic system

Rekha Priyadarshini, Gerard M. Raj, Deepak G. Shewade

Abstract


Pineal gland once considered as rudimentary or vestigial, has become a principal endocrine gland that regulates the body’s internal environment, after the discovery of melatonin - a hormone produced by it. Melatonin is also synthesized from extra-pineal sites such as retina, skin, platelets, bone marrow, and gastrointestinal tract. The chronobiological property of this hormone in maintaining the circadian rhythm by synchronizing with the dark-light cycle is well-established. Melatonin also possesses anti-inflammatory, anti-depressant, anti-oxidant, oncostatic, immunomodulatory, antiepileptic, and glucose-regulating properties. These pleiotropic effects of melatonin on diverse organ systems either through a receptor or non-receptor mediated pathways are under investigation. This review highlights the pathophysiological and pharmacological actions of melatonin along with melatonergic agonists in “real life” clinical practice.


Keywords


Melatonin, Pineal gland, Pleiotropy, Melatonergic drugs

Full Text:

PDF

References


Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol. 2014;6:127-37.

Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47:2336-48.

Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25(3-4):177-95.

Singh I. Textbook of Human Neuroanatomy. 7th Edition. New Delhi: Jaypee Brothers Medical Publishers Ltd.; 2006.

Ganong WF. Review of Medical Physiology. 22nd Edition. New York: McGraw-Hill Companies; 2005.

Rodwell VW. Conversion of amino acids to specialized products. In: Murray RK, Granner DK, Rodwell VW, editors. Harper’s Illustrated Biochemistry. 27th Edition. New York: McGraw-Hill Companies; 2006.

Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9(1):11-24.

Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29(5):325-33.

Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61(3):383-410.

National Research Council, March 22, 2006. Available at http://www.fluoridealert.org/researchers/nrc/. Cited 26 May 2015.

Claustrat B. Melatonin: an introduction to its physiological and pharmacological effects in humans. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer; 2014.

Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Sci World J. 2012;2012:640389.

De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013;14(6):12458-83.

Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol. 2007;3(4):221-8.

Rios ER, Venâncio ET, Rocha NF, Woods DJ, Vasconcelos S, Macedo D, et al. Melatonin: pharmacological aspects and clinical trends. Int J Neurosci. 2010;120(9):583-90.

Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773.

Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol. 2015;30(1):36-42.

Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin – A pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350-84.

Hardeland R. Melatonin’s antioxidant properties: molecular mechanisms. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer; 2014.

Csaba G. Hormones in the immune system and their possible role. A critical review. Acta Microbiol Immunol Hung. 2014;61(3):241-60.

Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci. 2013;14(4):8638-83.

Lissoni P. Melatonin in human cancer: therapeutic possibilities. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer; 2014.

Masters A, Pandi-Perumal SR, Seixas A, Girardin JL, McFarlane SI. Melatonin, the hormone of darkness: from sleep promotion to Ebola treatment. Brain Disord Ther. 2014;4(1):1000151.

Srinivasan V, Mohamed M, Kato H. Melatonin: its microbicidal properties and clinical applications. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer; 2014.

Rosales-Corral SA, Acuña-Castroviejo D, Coto-Montes A, Boga JA, Manchester LC, Fuentes-Broto L, et al. Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res. 2012;52(2):167-202.

Goyal A, Terry PD, Superak HM, Nell-Dybdahl CL, Chowdhury R, Phillips LS, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014;6:124.

United States Food and Drug Administration. Ramelteon label; 2005. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021782s011lbl.pdf. Updated 09 November 2010, Cited 16 April 2015.

Srinivasan V, Singh J, Brzezinski A, Zakaria R, Shillcutt SD, Brown GM. Jet lag: use of melatonin and melatonergic drugs. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and Melatonergic Drugs in Clinical Practice. New Delhi: Springer; 2014.

Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.

European Medicines Agency. Valdoxan-summary of product characteristics, 2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000915/WC500046227.pdf. Updated 04 December 2014, Cited 16 April 2015.

United States Food and Drug Administration. Tasimelteon Label, 2005. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205677s000lbl.pdf. Updated January 2014, Cited 16 April 2015.